Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment

References

• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):1–13.
   Web of Science ®Google Scholar
• Kanas G, Ge W, Quek RGW, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54–63.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang L, Hu J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. Cancer Commun. 2021;41(3):229–239.
   Web of Science ®Google Scholar
• He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35(8):2151–2165.
   PubMed Web of Science ®Google Scholar
• Mondello P, Mian M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Oncol. 2019;37(4):333–344.
   PubMed Web of Science ®Google Scholar
• Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
   PubMed Web of Science ®Google Scholar
• Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.
   PubMed Web of Science ®Google Scholar
• Dermani FK, Samadi P, Rahmani G, et al. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313–1325.
   PubMed Web of Science ®Google Scholar
• Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226:108707.
   PubMed Web of Science ®Google Scholar
• Cioroianu AI, Stinga PI, Sticlaru L, et al. Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis. Anal Cell Pathol. 2019;2019:8586354.
   Web of Science ®Google Scholar
• Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol. 2020;65:25–36.
   PubMed Web of Science ®Google Scholar
• Li Q, Oduro PK, Guo R, et al. Oncolytic viruses: immunotherapy drugs for gastrointestinal malignant tumors. Front Cell Infect Microbiol. 2022;12:921534.
   PubMed Web of Science ®Google Scholar
• Ishino R, Kawase Y, Kitawaki T, et al. Oncolytic virus therapy with HSV-1 for hematological malignancies. Mol Ther. 2021;29(2):762–774.
   PubMed Web of Science ®Google Scholar
• Wang G, Kang X, Chen KS, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11(1):1395.
   PubMed Web of Science ®Google Scholar
• Zhang W, Hu X, Liang J, et al. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Mol Ther Oncolytics. 2020;16:158–171.
   Google Scholar
• Lai C, Cole DE, Steinberg SM, et al. Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. Blood Adv. 2023;7(4):529–532.
   Google Scholar
• Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: b-cell non-Hodgkin lymphomas. Expert Rev Hematol. 2017;10(5):405–415.
   PubMed Web of Science ®Google Scholar
• Crombie JL, Armand P. Diffuse large B-cell lymphoma and high-grade B-cell lymphoma: genetic classification and its implications for prognosis and treatment. Hematol Oncol Clin North Am. 2019;33(4):575–585.
   PubMed Web of Science ®Google Scholar
• Xu PP, Huo YJ, Zhao WL. All roads lead to targeted diffuse large B-cell lymphoma approaches. Cancer Cell. 2022;40(2):131–133.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662.
   PubMed Web of Science ®Google Scholar
• Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16(10):2389–2402.
   PubMed Web of Science ®Google Scholar
• Bommareddy PK, Patel A, Hossain S, et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18(1):1–15.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zeng B, Hu X, et al. Oncolytic herpes simplex virus type 2 can effectively inhibit colorectal cancer liver metastasis by modulating the immune status in the tumor microenvironment and inducing specific antitumor immunity. Hum Gene Ther. 2021;32(3-4):203–215.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267–3285.
   PubMed Web of Science ®Google Scholar
• Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–741.
   PubMed Web of Science ®Google Scholar
• Paskeh MDA, Saebfar H, Mahabady MK, et al. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Life Sci. 2022;298:120463.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhou D, Yang J, et al. Doxorubicin promotes breast cancer cell migration and invasion via DCAF13. FEBS Open Bio. 2022;12(1):221–230.
   PubMed Web of Science ®Google Scholar
• Grant MKO, Seelig DM, Sharkey LC, et al. Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. PLoS One. 2019;14(2):e0212486.
   PubMed Web of Science ®Google Scholar
• Prasanna PL, Renu K, Valsala Gopalakrishnan A. New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci. 2020;250:117599.
   PubMed Web of Science ®Google Scholar
• Songbo M, Lang H, Xinyong C, et al. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–48.
   PubMed Web of Science ®Google Scholar
• Raja J, Ludwig JM, Gettinger SN, et al. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer. 2018;6:140.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu Y, Hu C, et al. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells. Int J Cancer. 2021;149(6):1369–1384.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–1122.
   PubMed Web of Science ®Google Scholar
• Kwon D, Kim S, Kim PJ, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology. 2016;68(7):1079–1089.
   PubMed Web of Science ®Google Scholar
• Kim S, Nam SJ, Park C, et al. High tumoral PD-L1 expression and low PD-1(+) or CD8(+) tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2019;8(9):e1626653.
   PubMed Web of Science ®Google Scholar
• Woo Y, Zhang Z, Yang A, et al. Novel chimeric immuno-oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer. J Am Coll Surg. 2020;230(4):709–717.
   PubMed Web of Science ®Google Scholar
• Storey KM, Lawler SE, Jackson TL. Modeling oncolytic viral therapy, immune checkpoint inhibition, and the complex dynamics of innate and adaptive immunity in glioblastoma treatment. Front Physiol. 2020;11:151.
   PubMed Web of Science ®Google Scholar